A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Complete resection (R0) and pathologically confirmed Stage IB to select IIIB NSCLC (8th edition)
Submission of pre-surgery blood sample and surgically resected tumor tissue slides or block
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Normal life expectancy excluding lung cancer mortality risk
Positive ctDNA status in plasma confirmed by central laboratory testing after surgical resection and prior to start of adjuvant therapy.
You may not be if
Resected NSCLC with positive margins (R1 or R2)
NSCLC with histology of large cell neuroendocrine carcinoma or sarcomatoid carcinoma
Mixed NSCLC and SCLC histology
Any prior therapy for lung cancer, including neoadjuvant therapy, or radiotherapy
NSCLC with an activating EGFR mutation or ALK fusion oncogene
Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
Clareo Health | A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
